Terns Pharmaceuticals, INC Form 4 insider transactions

Director Ann Elizabeth Taylor of Terns Pharmaceuticals received a stock option for 4,676 shares in lieu of a $20,000 cash retainer for the third and fourth quarters of 2024.

Director Hongbo Lu of Terns Pharmaceuticals acquired stock options in lieu of cash retainer fees, according to a recent SEC Form 4 filing.

Director Jeffrey Kindler of Terns Pharmaceuticals acquired stock options in lieu of cash retainer fees, according to a Form 4 filing.

Director Carl Gordon of Terns Pharmaceuticals receives a stock option for 4,676 shares in lieu of a $20,000 cash retainer.

Director David Fellows of Terns Pharmaceuticals acquired stock options in lieu of cash retainer fees, according to a recent SEC Form 4 filing.

Director Radhika Tripuraneni acquired stock options in Terns Pharmaceuticals, Inc. on June 10, 2024.

Director Ann Elizabeth Taylor acquired 32,000 stock options in Terns Pharmaceuticals on June 10, 2024, at an exercise price of $6.99.

Director Hongbo Lu acquired stock options for 32,000 shares of Terns Pharmaceuticals common stock on June 10, 2024.

Director Jill M. Quigley reports acquisition of 32,000 stock options in Terns Pharmaceuticals.

Director Carl Gordon acquired 32,000 stock options in Terns Pharmaceuticals, Inc. on June 10, 2024.

Director Jeffrey B. Kindler acquires 32,000 stock options in Terns Pharmaceuticals.

Director David A. Fellows of Terns Pharmaceuticals acquired 32,000 stock options on June 10, 2024, with vesting terms tied to the first anniversary of the grant date or the next Annual Meeting.

Seokho Bryan Yoon, COO and General Counsel of Terns Pharmaceuticals, reports purchasing 4,791 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) on May 31, 2024.

Mark J. Vignola, CFO of Terns Pharmaceuticals, reports purchasing 4,791 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.44 per share.

Melita Sun Jung, Chief Business Officer of Terns Pharmaceuticals, reports the acquisition of stock options for 475,000 shares.

Vivo Opportunity, LLC, a 10% owner of Terns Pharmaceuticals, Inc., executed a series of sales of common stock between April 1, 2024, and April 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Terns Pharmaceuticals CEO Amy Burroughs received stock options for 1,250,000 shares and 150,000 restricted stock units on March 1, 2024, as disclosed in a Form 4 filing.